BCL7C

Across TCGA pan-cancer cohorts, BCL7C RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated BCL7C data layer compared with 4 for mutation status and 8 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher BCL7C RNA is associated with worse overall survival. In most high-consensus cancer types, elevated BCL7C expression acts as an unfavorable survival marker, although some lineages such as OV and THCA show a favorable association.

LIHC, ACC, and LGG are the cancer types where BCL7C RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.608	0.759	<.001	86	view →
ACC	DFS	Median	All	0.221	0.664	<.001	84	view →
LGG	DFS	Median	All	0.640	0.829	<.001	50	view →
KICH	OS	Median	III,IV	0.347	0.942	.001	47	view →
SKCM	OS	Tertile	All	0.835	0.921	<.001	37	view →
OV	OS	Quartile	III,IV	0.898	0.773	.003	32	view →
KIRP	OS	Quartile	II,III,IV	0.519	0.850	.006	18	view →
PRAD	DFS	Tertile	All	0.711	0.906	.002	18	view →
BLCA	OS	Quartile	IV	0.189	0.572	.003	17	view →
THCA	DFS	Median	All	0.894	0.763	.003	17	view →
SCLC	OS	Tertile	II,III,IV	0.264	0.653	.004	15	view →
UCEC	DFS	Quartile	IV	0.385	0.786	.009	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

BCL7C–LIHC (OS)

Open the LIHC breakdown →